235 related articles for article (PubMed ID: 7815748)
1. [Numerical and functional alterations in T and B lymphocyte subpopulations in CAPD patients treated with recombinant human erythropoietin].
Tanabe R
Nihon Jinzo Gakkai Shi; 1994 Oct; 36(10):1159-68. PubMed ID: 7815748
[TBL] [Abstract][Full Text] [Related]
2. Evidence that treatment of ESRD patients with recombinant human erythropoietin induces immunosuppression without affecting the distribution of peripheral blood mononuclear cell subpopulations.
Steffensen G; Aunsholt NA; Povlsen JV
Clin Nephrol; 1996 Feb; 45(2):98-103. PubMed ID: 8846537
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin treatment: investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome. Overall results.
Phair JP; Abels RI; McNeill MV; Sullivan DJ
Arch Intern Med; 1993 Dec; 153(23):2669-75. PubMed ID: 8250662
[TBL] [Abstract][Full Text] [Related]
4. Autonomic dysfunction and the development of hypertension in patients treated with recombinant human erythropoietin (r-HuEPO).
Roger SD; Baker LR; Raine AE
Clin Nephrol; 1993 Feb; 39(2):103-10. PubMed ID: 8448912
[TBL] [Abstract][Full Text] [Related]
5. [Anemia in patients on continuous ambulatory peritoneal dialysis (CAPD)].
Tokuda Y; Itou H; Uchida Y; Azuma K; Ohtsuka H; Uomizu K; Yamashita W; Harada R; Nakashima A; Morita T
Fukuoka Igaku Zasshi; 1989 Jul; 80(7):379-84. PubMed ID: 2807127
[TBL] [Abstract][Full Text] [Related]
6. [The treatment of anemia of hemodialysis patients using recombinant human erythropoietin: comparison between intravenous and subcutaneous administration].
Zehnder C; Blumberg A
Schweiz Med Wochenschr; 1990 Feb; 120(7):217-20. PubMed ID: 2309110
[TBL] [Abstract][Full Text] [Related]
7. Current use of recombinant human erythropoietin (r-huEPO) in the management of symptomatic anaemia in patients with myelodysplastic syndromes (MDS).
Marques da Costa R
Sangre (Barc); 1994 Apr; 39(2):105-10. PubMed ID: 8059287
[TBL] [Abstract][Full Text] [Related]
8. Alterations in sex hormones and sexual function of patients with renal failure treated with recombinant human erythropoietin.
Suzuki H; Murakami M; Ichihara A; Saruta T
Nihon Jinzo Gakkai Shi; 1992 Jan; 34(1):79-84. PubMed ID: 1593800
[TBL] [Abstract][Full Text] [Related]
9. Lymphocyte subset counts in continuous ambulatory peritoneal dialysis patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors.
Grzegorzewska AE; Leander M
Adv Perit Dial; 2002; 18():6-11. PubMed ID: 12402577
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination].
Wiecek A; Kokot F; Grzeszczak W; Klin M
Pol Tyg Lek; 1990 Sep 17-24; 45(38-39):782-6. PubMed ID: 2095546
[TBL] [Abstract][Full Text] [Related]
11. [The effects of r-HuEPO on platelet function and coagulation factors in hemodialysis patients].
Kinugasa E; Nabeshima K; Niikura K; Kawabe S; Akizawa T; Kitaoka T; Koshikawa S
Nihon Jinzo Gakkai Shi; 1990 Oct; 32(10):1109-16. PubMed ID: 2287103
[TBL] [Abstract][Full Text] [Related]
12. Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.
Cowgill LD; James KM; Levy JK; Browne JK; Miller A; Lobingier RT; Egrie JC
J Am Vet Med Assoc; 1998 Feb; 212(4):521-8. PubMed ID: 9491159
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients.
Frenken LA; Verberckmoes R; Michielsen P; Koene RA
Nephrol Dial Transplant; 1989; 4(9):782-6. PubMed ID: 2516609
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of recombinant erythropoietin after subcutaneous or intraperitoneal administration to patients on CAPD.
Icardi A; Paoletti E; Molinelli G
Adv Perit Dial; 1990; 6():292-5. PubMed ID: 1982830
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte subsets in the course of continuous ambulatory peritoneal dialysis.
Grzegorzewska AE; Leander M
Adv Perit Dial; 2001; 17():10-4. PubMed ID: 11510253
[TBL] [Abstract][Full Text] [Related]
17. Infrequent dosing of subcutaneous erythropoietin for the treatment of anemia in patients on CAPD.
Bunke M; Bartlett DK; Brier ME; Golper TA
Adv Perit Dial; 1993; 9():331-5. PubMed ID: 8105957
[TBL] [Abstract][Full Text] [Related]
18. High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study.
Stebler C; Tichelli A; Dazzi H; Gratwohl A; Nissen C; Speck B
Exp Hematol; 1990 Dec; 18(11):1204-8. PubMed ID: 2226680
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of blood and peritoneal lymphocytes from continuous ambulatory peritoneal dialysis patients.
Lewis SL; Bonner PN; Cooper CL; Holmes CJ
J Clin Lab Immunol; 1992 Jan; 37(1):3-19. PubMed ID: 1339234
[TBL] [Abstract][Full Text] [Related]
20. [Influence of iron metabolism on the efficacy of r-HuEPO (recombinant human erythropoietin) treatment of anemia in children on hemodialysis].
Pela I; Lavoratti GC; Materassi M; Burgio G; Bartolozzi G
Pediatr Med Chir; 1991; 13(5):475-7. PubMed ID: 1788107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
